Stenabolic

The stenabolic uk problem nobody mentions in the listing

SR9009 is a REV-ERB agonist studied for effects on circadian and metabolic regulation. In rodent studies it increased mitochondrial content and endurance capacity, which produced the “exercise in a bottle” framing that still follows it around. This section holds 10 lines from £67 to £162, averaging near £102.

The problem is administration. In the studies that generated those results, SR9009 was injected. Its oral bioavailability is very poor — a widely cited figure puts it in the low single digits of a percent.

Why that matters more than the mechanism

Almost every product sold as stenabolic, here included, is an oral preparation. If only a few percent of an oral dose reaches circulation, the exposure achieved bears little relationship to the exposure that produced the published effects.

This is not a claim that it does nothing. It is a claim that the rodent endurance data is being used to sell a route of administration that data never tested, and buyers deserve to know that before comparing it against anything else.

Not a SARM either

Like cardarine, SR9009 is filed under SARMs by convention rather than pharmacology. It does not bind the androgen receptor, is not suppressive, and does not require post cycle therapy.

What is actually known

Rodent data on mitochondrial biogenesis and endurance is genuine. Human data is effectively absent. Long-term safety is unstudied. The short half-life means the dosing schedules that circulate are frequent, which compounds the bioavailability issue rather than solving it.

Anyone weighing this against fat burners with decades of human use should factor in that the comparison is between a well-characterised drawback and an unmeasured unknown.

Status

SR9009 is not a licensed medicine in the UK, is sold for research purposes, and is prohibited in sport. Supplier checks are covered in how to check a brand is genuine. Nothing here is medical advice.

Stability is a second problem

SR9009 has limited stability in solution, so storage conditions and formulation affect how much intact compound is present by the time it is taken. Combined with poor oral absorption, that means two products with identical labels can deliver quite different exposures.

What a realistic expectation looks like

Modest, if anything, and difficult to distinguish from the training that accompanies it. Anyone reporting dramatic results from oral SR9009 is describing something the pharmacology does not readily explain.

Frequently asked questions

Does oral SR9009 work?
Oral bioavailability is very poor. The published effects came from injected administration in animals.

Is it a SARM?
No. It is a REV-ERB agonist, not an androgen receptor compound, and it is not suppressive.

Is there human data?
Effectively none. The evidence base is rodent studies.

Does it need PCT?
No — it does not suppress natural testosterone production.

Why is it dosed so frequently?
The half-life is short. That does not overcome the absorption problem, it just increases how often it is taken.